Tesamorelin Study for COPD Muscle Wasting Terminated Early Due to Low Enrollment

A significant proportion of Chronic Obstructive Pulmonary Disease (COPD) subjects experience muscle wasting, a debilitating condition associated with increased morbidity, impaired physical functioning, and a poor quality of life. This muscle loss significantly reduces muscle strength and exercise performance in affected individuals. This study aimed to investigate if tesamorelin could improve lean body mass in stable COPD patients experiencing muscle wasting.

Due to critically low enrollment, with only 3 subjects actually participating, this Phase 2 study was terminated prematurely in December 2011. Consequently, no statistically significant or meaningful data regarding the efficacy of tesamorelin on lean body mass in COPD patients could be collected or analyzed. The most critical finding is that the study's early termination with only 3 enrolled subjects prevented any conclusive assessment of tesamorelin's impact on muscle wasting in COPD. Without sufficient data, it was impossible to compare treatment groups (e.g., tesamorelin 2 mg vs. placebo) or draw any conclusions about potential benefits or adverse effects. The study's inability to progress beyond initial enrollment means its primary objective of investigating lean body mass changes remains unanswered.